Sustained virological response: A milestone in the treatment of chronic hepatitis C

World Journal of Gastroenterology

Volumn 19, Issue 18, 2013, Pages 2793-2798

  Morisco, Filomena ^a   Granata, Rocco ^a   Stroffolini, Tommaso ^b   Guarino, Maria ^a   Donnarumma, Laura ^a   Gaeta, Laura ^a   Loperto, Ilaria ^a   Gentile, Ivan ^a   Auriemma, Francesco ^a   Caporaso, Nicola ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Antiviral therapy; Cirrhosis; Fibrosis; Hepatitis C virus; Sustained virological response

Indexed keywords

INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ARTICLE; BLEEDING; DEATH; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TREATMENT RESPONSE;

EID: 84877795646     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i18.2793     Document Type: Article

References (32)

1. World Health Organization. Hepatitis C- global prevalence (update). Available from: URL: http: //www.who.int/docstore/ wer/pdf/2000/wer7503.pdf
2. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, Seki S, Kobayashi K, Otani S. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-1055. [PMID: 7564784 DOI: 10.1016/S0140-6736(95)91739-X]
3. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999; 131: 174-181. [PMID: 10428733]
4. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003; 362: 2095-2100. [PMID: 14697814 DOI: 10.1016/ S0140-6736(03)15109-4]
5. Yoshida H, Tateishi R, Arakawa Y, Sata M, Fujiyama S, Nishiguchi S, Ishibashi H, Yamada G, Yokosuka O, Shiratori Y, Omata M. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut 2004; 53: 425-430. [PMID: 14960528 DOI: 10.1136/gut.2003.030353]
6. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29 Suppl 1: 74-81. [PMID: 19207969 DOI: 10.1111/ j.1478-3231.2008.01934.x]
7. Bruno S, Facciotto C. The natural course of HCV infection and the need for treatment. Ann Hepatol 2008; 7: 114-119. [PMID: 18626427]
8. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000; 20: 17-35. [PMID: 10895429 DOI: 10.1055/s-2000-9505]
9. Ascione A, Tartaglione T, Di Costanzo GG. Natural history of chronic hepatitis C virus infection. Dig Liver Dis 2007; 39 Suppl 1: S4-S7. [PMID: 17936222 DOI: 10.1016/S1590- 8658(07)80003-X]
10. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-832. [PMID: 9121257]
11. Formann E, Steindl-Munda P, Hofer H, Jessner W, Bergholz U, Gurguta C, Ferenci P. Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy. Aliment Pharmacol Ther 2006; 23: 507-511. [PMID: 16441471 DOI: 10.1111/j.1365-2036.2006.02785.x]
12. Tsuda N, Yuki N, Mochizuki K, Nagaoka T, Yamashiro M, Omura M, Hikiji K, Kato M. Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy. J Med Virol 2004; 74: 406-413. [PMID: 15368524 DOI: 10.1002/jmv.20190]
13. Hung CH, Lee CM, Lu SN, Wang JH, Hu TH, Tung HD, Chen CH, Chen WJ, Changchien CS. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virusrelated cirrhosis. J Viral Hepat 2006; 13: 409-414. [PMID: 16842444 DOI: 10.1111/j.1365-2893.2005.00707.x]
14. Arase Y, Ikeda K, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Akuta N, Someya T, Koyama R, Hosaka T, Sezaki H, Kobayashi M, Kumada H. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C. Intervirology 2007; 50: 16-23. [PMID: 17164553 DOI: 10.1159/000098958]
15. Annicchiarico BE, Siciliano M, Avolio AW, Grillo RL, Bombardieri G. A 5-year prospective study of the late resolution of chronic hepatitis C after antiviral therapy. Aliment Pharmacol Ther 2007; 25: 1039-1046. [PMID: 17439504 DOI: 10.1111/j.1365-2036.2007.03295.x]
16. Koh C, Heller T, Haynes-Williams V. Clinical, virological, biochemical outcomes after 20 years of sustained virological response (SVR) in chronic hepatitis C: The NIH experience. 61th Annual Meeting of the American Association for the Study of Liver Diseases. Available from: URL: http: //www.natap.org/2010/AASLD/AASLD_25.htm
17. Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Dieterich DT, Abergel A, Pessôa MG, Lin A, Tietz A, Connell EV, Diago M. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010; 139: 1593-1601. [PMID: 20637202 DOI: 10.1053/j.gastro.2010.07.009]
18. George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 2009; 49: 729-738. [PMID: 19072828 DOI: 10.1002/hep.22694]
19. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699. [PMID: 7560864 DOI: 10.1016/0168-8278(95)80226-6]
20. Tsochatzis EA, Gurusamy KS, Ntaoula S, Cholongitas E, Davidson BR, Burroughs AK. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a metaanalysis of diagnostic accuracy. J Hepatol 2011; 54: 650-659. [PMID: 21146892 DOI: 10.1016/j.jhep.2010.07.033]
21. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338. [PMID: 10518312 DOI: 10.1055/s-2007-1007122]
22. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, Manns MP, Hansen BE, Schalm SW, Janssen HL. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677-684. [PMID: 18025443]
23. Turner AJ, Hick PE. Inhibition of aldehyde reductase by acidic metabolites of the biogenic amines. Biochem Pharmacol 1975; 24: 1731-1733. [PMID: 16 DOI: 10.1080/00365520510015 467]
24. Ikeda M, Fujiyama S, Tanaka M, Sata M, Ide T, Yatsuhashi H, Watanabe H. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. J Gastroenterol 2005; 40: 148-156. [PMID: 15770398 DOI: 10.1007/s00535-004-1519-2]
25. Imazeki F, Yokosuka O, Fukai K, Saisho H. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. Hepatology 2003; 38: 493-502. [PMID: 12883494 DOI: 10.1053/jhep.2003.50329]
26. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, Kilani A, Areias J, Auperin A, Benhamou JP, Degott C, Erlinger S. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon- alpha therapy. Ann Intern Med 1997; 127: 875-881. [PMID: 9382365]
27. Cammà C, Di Marco V, Lo Iacono O, Almasio P, Giunta M, Fuschi P, Vaccaro A, Fabiano C, Magrin S, Di Stefano R, Bonura C, Pagliaro L, Craxì A. Long-term course of interferon- treated chronic hepatitis C. J Hepatol 1998; 28: 531-537. [PMID: 9566819 DOI: 10.1016/S0168-8278(98)80274-2]
28. Reichard O, Glaumann H, Frydén A, Norkrans G, Wejstål R, Weiland O. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alphainterferon. J Hepatol 1999; 30: 783-787. [PMID: 10365802 DOI: 10.1016/S0168-8278(99)80129-9]
29. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH, Albrecht J. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-1313. [PMID: 11984517 DOI: 10.1053/gast.2002.33023]
30. D'Ambrosio R, Aghemo A, Rumi MG, Ronchi G, Donato MF, Paradis V, Colombo M, Bedossa P. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology 2012; 56: 532-543. [PMID: 22271347 DOI: 10.1002/hep.25606]
31. Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-1457. [PMID: 14647056 DOI: 10.1016/S0270-9139(03)80411-1]
32. Ellis EL, Mann DA. Clinical evidence for the regression of liver fibrosis. J Hepatol 2012; 56: 1171-1180. [PMID: 22245903 DOI: 10.1016/j.jhep.2011.09.024]